Cardiovascular disease (CVD) is the leading cause of death in patients with diabetes, with fewer than 1 in 5 adults with Type 2 diabetes (T2D) in the U.S. meeting suggested targets to reduce elevated heart disease risk.¹

A 2022 Scientific Statement from the American Heart Association details an updated, evidence-based approach to managing cardiovascular disease (CVD) in adults with type 2 diabetes (T2D). The report stresses the importance of lifestyle modifications, including increased physical activity, healthy nutrition, obesity and weight management, smoking cessation, reduced alcohol use, and psychosocial care. Blood glucose control, blood pressure management, lipid targets, and updated imaging tests are also discussed as part of a comprehensive approach to CVD risk reduction.

Recent clinical trials with new antihyperglycemic agents demonstrate cardiovascular safety and improved outcomes, emphasizing the importance of these newer medications on improving cardiovascular health outcomes (Table 2).

Noting that social determinants of health account for 80-90% of health outcomes,² authors call for both direct and upstream solutions to manage cardiovascular risk factors in patients with T2D.